TITUSVILLE, N.J., May 24 /PRNewswire/ --New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone ...

A Drug's Impact on Global Symptoms and Its Effect on Positive Symptoms Are the Attributes that Most Influence Surveyed Psychiatrists' Prescribing Decisions in Schizophrenia, According to a New Report ...

August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...

The FINANCIAL — A study published in The Journal of Clinical Psychiatry shows that long-acting INVEGA SUSTENNA (paliperidone palmitate) was effective six months longer than commonly prescribed oral ...

The 6-month study examined the safety, efficacy, and tolerability of Aristada in patients with schizophrenia who had an inadequate response or intolerance to Invega Sustenna. The 6-month, open-label, ...

Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional ...

SAN DIEGO -- Among patients with schizophrenia, most preferred long-acting injectable antipsychotics when given a choice, a researcher reported here. A post-hoc analysis of a randomized, controlled ...

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...